GLP-1/Weight Loss

The insurer is offering at-home defibrillators and health tech, aiming to redefine its role from covering death to extending life. But what does it mean for you?

European digital health firm Apomeds launches in the UK, targeting the booming telehealth market with a focus on discreet, high-demand treatments.

Biocon merges its biosimilar and generics units, appointing 30-year veteran Shreehas Tambe as CEO to forge a new globally-scaled biopharma enterprise.

Telehealth platforms like ReflexMD offer cheaper, compounded GLP-1s for weight loss. But what are the risks, and what do consumers need to know?

As its new obesity drug enters a key trial, Biohaven bets on a novel approach: reducing fat while preserving precious muscle mass. Can it redefine weight loss?

Tenax Therapeutics achieves a major clinical trial goal, moving its promising drug TNX-103 closer to becoming the first approved therapy for a deadly heart condition.

A new partnership leverages advanced AI and metabolomics to find novel drug targets for rare metabolic disorders, offering new hope for millions worldwide.

One in 10 Canadians has kidney disease, often with no symptoms. Experts urge immediate action as this silent crisis strains lives and our healthcare system.

Curanex Pharmaceuticals hits a key manufacturing milestone for Phyto-N, a botanical drug with a 30-year history, advancing its quest for FDA approval.

A new report shows patients are rejecting 'overdone' looks for subtle, strategic care, driven by Ozempic, menopause, and a desire for authenticity.

A federal court ruling against Corcept Therapeutics clears a key legal hurdle for Teva's generic Cushing's syndrome drug, rattling investors.

Bausch + Lomb beats Q4 revenue forecasts, propelled by its blockbuster dry eye drug MIEBO, and issues a confident financial outlook for 2026.

Facing massive revenue declines and a shrinking coach network due to GLP-1 drugs, Medifast bets its future on a risky pivot from weight loss to metabolic health.

Bausch Health heads to a key finance conference to address investor concerns over its massive debt, upcoming patent cliffs, and future strategic direction.

Atlanta's World Neuroscience Day Conference returns to explore the brain-heart connection, demystify clinical trials, and empower a growing community.

Nicox's novel glaucoma drug NCX 470 receives positive FDA feedback, keeping its 2026 U.S. market submission on track to challenge a $7B industry.

Disc Medicine's promising EPP drug hits a major roadblock as the FDA seeks more data, delaying hope for patients and setting up a high-stakes trial.

A new online pharmacy is challenging the 'prescribe and forget' model for weight loss drugs, offering integrated clinical care to combat safety concerns.

After a major trial failure tanked its stock, Rezolute pins its hopes on a second drug program and a crucial FDA meeting to chart a path forward.

Clinical-stage biotech BioVie announces its novel anti-inflammatory drug, bezisterim, will be featured at a key psychiatric conference for its potential.